Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Alzheimer's Disease

Free Subscription Articles published in Lancet Neurol Retrieve available abstracts of 67 articles: HTML format

Single Articles

November 2026
1. BARTON ME, Byrnes W, van den Steen B, van Tricht H, et al
   Safety, tolerability, and efficacy of bepranemab in people living with prodromal-to-mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2 trial.
   Lancet Neurol. 2026 Nov 10:S1474-4422(26)00357.
   PubMed     Abstract available
   
   
   October 2026
2. GRAFF-RADFORD J, Karliner L, Barnes DE, Frisoni GB, et al
   Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change.
   Lancet Neurol. 2026;25:952-964.
   PubMed     Abstract available
   
   
   
3. BENZINGER TLS, Cogswell PM, Arani A, Chaney AM, et al
   Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy.
   Lancet Neurol. 2026;25:939-951.
   PubMed     Abstract available
   
   
   
4. TEUNISSEN CE, Vermunt L, Barthelemy NR, Benzinger TLS, et al
   Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders.
   Lancet Neurol. 2026;25:926-938.
   PubMed     Abstract available
   
   
   
5. LAN G, Guo T
   Charting the future of biomarkers and therapy in Alzheimer's disease.
   Lancet Neurol. 2026;25:879-880.
   PubMed    
   
   
   
6. THE LANCET NEUROLOGY
   Alzheimer's disease testing needs evidence, ethics, and equity.
   Lancet Neurol. 2026;25:873.
   PubMed    
   
   
   September 2026
7. MU R, Hofmann A, Gong K, Liu M, et al
   Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort study.
   Lancet Neurol. 2026 Sep 24:S1474-4422(26)00284.
   PubMed     Abstract available
   
   
   June 2026
8. PATEL M, Feng W, Mckay NS, Millar PR, et al
   Identification of genetic modifiers of autosomal dominant Alzheimer's disease: a genome-wide association study.
   Lancet Neurol. 2026;25:581-590.
   PubMed     Abstract available
   
   
   
9. KOSIK KS
   Genetic modifiers in autosomal dominant Alzheimer's disease.
   Lancet Neurol. 2026;25:537-538.
   PubMed    
   
   
   April 2026
10. MATTSSON-CARLGREN N, Palmqvist S, Horie K, Barthelemy N, et al
    Integration of plasma eMTBR-tau243 and p-tau217 in the diagnosis and stratification of Alzheimer's disease: a prospective cohort study.
    Lancet Neurol. 2026;25:357-367.
    PubMed     Abstract available
    
    
    
11. ASHTON NJ
    Biologically informed blood testing in Alzheimer's disease.
    Lancet Neurol. 2026;25:327-329.
    PubMed    
    
    
    March 2026
12. REIMAN EM, Alexander RC, Langbaum JB, Aisen PS, et al
    A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA.
    Lancet Neurol. 2026;25:268-278.
    PubMed     Abstract available
    
    
    
13. SCHNEIDER L
    When Alzheimer's disease prevention becomes policy: regulatory speed, commercialisation, and risk.
    Lancet Neurol. 2026;25:219-220.
    PubMed    
    
    
    
14. THE LANCET NEUROLOGY
    Stopping Alzheimer's disease before symptoms start.
    Lancet Neurol. 2026;25:213.
    PubMed    
    
    
    February 2026
15. TARIOT PN, Lopera FS, Rios-Romenets S, Sink KM, et al
    Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1(Glu280Ala) mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled tri
    Lancet Neurol. 2026;25:147-159.
    PubMed     Abstract available
    
    
    
16. FORTEA J, Llibre-Guerra J, O'Connor A, Levin J, et al
    Lessons from the Colombian kindred: rethinking Alzheimer's prevention.
    Lancet Neurol. 2026;25:117-119.
    PubMed    
    
    
    January 2026
17. VOSSEL K, Johnson EL, Cretin B, Matsumoto R, et al
    Epileptic activity in Alzheimer's disease: emerging insights and therapeutic implications.
    Lancet Neurol. 2026 Jan 22:S1474-4422(25)00425.
    PubMed     Abstract available
    
    
    
18. DEVINSKY O
    Alzheimer's disease and epileptic activity: uncertainties abound.
    Lancet Neurol. 2026 Jan 22:S1474-4422(25)00496.
    PubMed    
    
    
    
19. MORGAN J
    Takeshi Iwatsubo: a pioneer in Alzheimer's disease research.
    Lancet Neurol. 2026;25:33.
    PubMed    
    
    
    December 2025
20. RABINOVICI GD
    Progress in Alzheimer's disease: The Lancet Series.
    Lancet Neurol. 2025;24:991-992.
    PubMed    
    
    
    
21. SCHOLZ SW, Okubadejo NU, Prakash P, Liddelow SA, et al
    Advances in the genetics and pathology of Lewy body dementia.
    Lancet Neurol. 2025;24:1026-1037.
    PubMed     Abstract available
    
    
    
22. JACK CR JR, Hu M, Wiste HJ, Knopman DS, et al
    Lifetime and 10-year absolute risk of cognitive impairment in relation to amyloid PET severity: a retrospective, longitudinal cohort study.
    Lancet Neurol. 2025;24:1016-1025.
    PubMed     Abstract available
    
    
    November 2025
23. BOON BDC, Piura YD, Moloney CM, Chalk JL, et al
    Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control study.
    Lancet Neurol. 2025;24:931-944.
    PubMed     Abstract available
    
    
    
24. IWATSUBO T
    Neuropathology of Alzheimer's disease after anti-amyloid beta antibody treatment.
    Lancet Neurol. 2025;24:897-899.
    PubMed    
    
    
    September 2025
25. RAFII MS, Schlachetzki Z, Barroeta I, Head E, et al
    Down syndrome and Alzheimer's disease: insights into biomarkers, clinical symptoms, and pathology.
    Lancet Neurol. 2025;24:753-762.
    PubMed     Abstract available
    
    
    
26. THERRIAULT J, Brum WS, Trudel L, Macedo AC, et al
    Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
    Lancet Neurol. 2025;24:740-752.
    PubMed     Abstract available
    
    
    
27. RYAN NS
    Alzheimer's disease in Down syndrome: progress and promise.
    Lancet Neurol. 2025;24:717-718.
    PubMed    
    
    
    
28. KESHAVAN A, Algeciras-Schimnich A
    Plasma phosphorylated tau for Alzheimer's disease diagnosis.
    Lancet Neurol. 2025;24:715-717.
    PubMed    
    
    
    August 2025
29. LI Y, Llibre-Guerra JJ, Supnet C, Atri A, et al
    Interpreting the evidence on gantenerumab for dominantly inherited Alzheimer's disease - Authors' reply.
    Lancet Neurol. 2025;24:635-636.
    PubMed    
    
    
    
30. CHENG Y, Zhang Y, Zhang S, Shang H, et al
    Interpreting the evidence on gantenerumab for dominantly inherited Alzheimer's disease.
    Lancet Neurol. 2025;24:634.
    PubMed    
    
    
    
31. WALSH S, Howard R, Richard E, Milne R, et al
    Interpreting the evidence on gantenerumab for dominantly inherited Alzheimer's disease.
    Lancet Neurol. 2025;24:634.
    PubMed    
    
    
    July 2025
32. TEUNISSEN C, Duits F
    Plasma biomarkers for diagnosis and prognosis in Down syndrome-related Alzheimer's disease.
    Lancet Neurol. 2025;24:561-562.
    PubMed    
    
    
    June 2025
33. MARINO C, Malotaux V, Giudicessi A, Aguillon D, et al
    Protective genetic variants against Alzheimer's disease.
    Lancet Neurol. 2025;24:524-534.
    PubMed     Abstract available
    
    
    
34. THE LANCET NEUROLOGY
    A genetic framework for Alzheimer's disease prevention.
    Lancet Neurol. 2025;24:471.
    PubMed    
    
    
    May 2025
35. MATAR E, Halliday GM
    Biological effects of pathologies in Lewy body diseases: why timing matters.
    Lancet Neurol. 2025;24:441-455.
    PubMed     Abstract available
    
    
    April 2025
36. BATEMAN RJ, Li Y, McDade EM, Llibre-Guerra JJ, et al
    Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.
    Lancet Neurol. 2025;24:316-330.
    PubMed     Abstract available
    
    
    
37. SCHOTT JM
    Amyloid immunotherapy to prevent Alzheimer's disease: the wrong drug at the right time?
    Lancet Neurol. 2025;24:279-281.
    PubMed    
    
    
    February 2025
38. BLANQUIE O, Guizzaro L, Herold R, Haberkamp M, et al
    EU regulatory horizons for Alzheimer's disease.
    Lancet Neurol. 2025;24:96-97.
    PubMed    
    
    
    
39. MASTERS CL
    Should the preclinical stage of Alzheimer's disease be disclosed?
    Lancet Neurol. 2025;24:94-95.
    PubMed    
    
    
    January 2025
40. THE LANCET NEUROLOGY
    Bridging the diagnostic gap in Alzheimer's disease.
    Lancet Neurol. 2025;24:1.
    PubMed    
    
    
    December 2024
41. SCHWORER EK, Zammit MD, Wang J, Handen BL, et al
    Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study.
    Lancet Neurol. 2024;23:1214-1224.
    PubMed     Abstract available
    
    
    
42. HUNDAL H
    Frank Longo: taking on Alzheimer's disease.
    Lancet Neurol. 2024;23:1188.
    PubMed    
    
    
    
43. RAFII MS
    The amyloid clock: mapping Alzheimer's disease in Down syndrome.
    Lancet Neurol. 2024;23:1173-1174.
    PubMed    
    
    
    October 2024
44. STIRRUPS R
    Navigating the roads ahead for Alzheimer's disease.
    Lancet Neurol. 2024;23:971.
    PubMed    
    
    
    
45. HYMAN BT
    Amyloid removal and the appearance of brain volume loss.
    Lancet Neurol. 2024;23:957-958.
    PubMed    
    
    
    
46. BELDER CRS, Boche D, Nicoll JAR, Jaunmuktane Z, et al
    Brain volume change following anti-amyloid beta immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy.
    Lancet Neurol. 2024;23:1025-1034.
    PubMed     Abstract available
    
    
    September 2024
47. THE LANCET NEUROLOGY
    The evolving paradigm of Alzheimer's disease diagnosis.
    Lancet Neurol. 2024;23:845.
    PubMed    
    
    
    August 2024
48. OHRY A
    Ezio Giacobini: a leader in Alzheimer's disease research.
    Lancet Neurol. 2024;23:768.
    PubMed    
    
    
    July 2024
49. SCHULTZ SA, Liu L, Schultz AP, Fitzpatrick CD, et al
    gamma-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).
    Lancet Neurol. 2024 Jul 26:S1474-4422(24)00236.
    PubMed     Abstract available
    
    
    
50. POTIER MC, Steiner H, Chavez-Gutierrez L
    Amyloid beta, gamma-secretase, and familial Alzheimer's disease.
    Lancet Neurol. 2024 Jul 26:S1474-4422(24)00292.
    PubMed    
    
    
    June 2024
51. KAPASI A, Schneider JA
    Speculation on the transmissibility of Alzheimer's disease.
    Lancet Neurol. 2024;23:555-556.
    PubMed    
    
    
    May 2024
52. WISCH JK, McKay NS, Boerwinkle AH, Kennedy J, et al
    Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2024;23:500-510.
    PubMed     Abstract available
    
    
    
53. NORDBERG A
    Insights into the progression of genetic Alzheimer's disease from tau PET.
    Lancet Neurol. 2024;23:453-454.
    PubMed    
    
    
    March 2024
54. FRISONI GB, Festari C, Massa F, Cotta Ramusino M, et al
    European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders.
    Lancet Neurol. 2024;23:302-312.
    PubMed     Abstract available
    
    
    
55. THE LANCET NEUROLOGY
    Dementia diagnosis in the anti-amyloid era.
    Lancet Neurol. 2024;23:219.
    PubMed    
    
    
    February 2024
56. CHAPLEAU M, La Joie R, Yong K, Agosta F, et al
    Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.
    Lancet Neurol. 2024;23:168-177.
    PubMed     Abstract available
    
    
    
57. REIMAN EM, Cummings JL, Langbaum JB, Mattke S, et al
    A chance to prevent Alzheimer's disease sooner than you think.
    Lancet Neurol. 2024;23:144-145.
    PubMed    
    
    
    
58. BEJANIN A, Villain N
    Posterior cortical atrophy: new insights into treatments and biomarkers for Alzheimer's disease.
    Lancet Neurol. 2024;23:127-128.
    PubMed    
    
    
    January 2024
59. DELRIEU J, Andrieu S, Vellas B
    Dementia research in 2023: the year of anti-amyloid immunotherapy.
    Lancet Neurol. 2024;23:13-15.
    PubMed    
    
    
    December 2023
60. RANSCOMBE P
    Powerful series profiles rare forms of dementia.
    Lancet Neurol. 2023;22:1112.
    PubMed    
    
    
    November 2023
61. SCHLEPCKOW K, Morenas-Rodriguez E, Hong S, Haass C, et al
    Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease.
    Lancet Neurol. 2023;22:1048-1060.
    PubMed     Abstract available
    
    
    September 2023
62. JAGUST WJ, Teunissen CE, DeCarli C
    The complex pathway between amyloid beta and cognition: implications for therapy.
    Lancet Neurol. 2023;22:847-857.
    PubMed     Abstract available
    
    
    July 2023
63. BELDER CRS, Schott JM, Fox NC
    Preparing for disease-modifying therapies in Alzheimer's disease.
    Lancet Neurol. 2023 Jul 14:S1474-4422(23)00274.
    PubMed    
    
    
    
64. FRISONI GB
    Complexity is the simple truth about Alzheimer's disease.
    Lancet Neurol. 2023 Jul 13:S1474-4422(23)00176.
    PubMed    
    
    
    June 2023
65. THE LANCET NEUROLOGY
    Treatment for Alzheimer's disease: time to get ready.
    Lancet Neurol. 2023;22:455.
    PubMed    
    
    
    
66. MASON M, Bacioglu M, Vivacqua G, Spillantini MG, et al
    Targeting tau degradation: a viable therapeutic approach?
    Lancet Neurol. 2023;22:462-464.
    PubMed    
    
    
    May 2023
67. LANGWORTH-GREEN C, Patel S, Jaunmuktane Z, Jabbari E, et al
    Chronic effects of inflammation on tauopathies.
    Lancet Neurol. 2023;22:430-442.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum